bioAffinity Technologies Enters Sales Agreement with WallachBeth

bioAffinity Technologies, Inc. ( (BIAF) ) has provided an update.

On May 22, 2025, bioAffinity Technologies, Inc. entered into an At-The-Market Issuance Sales Agreement with WallachBeth Capital LLC to facilitate the sale of its common stock through an ‘at the market offering’ program. This agreement allows the company to sell shares directly on the Nasdaq Capital Market or other trading platforms, with WallachBeth acting as the sales agent. The agreement provides flexibility in terms of the number of shares sold and the timing, while also allowing for termination by either party under certain conditions. The arrangement is expected to enhance the company’s financial flexibility and market presence.

The most recent analyst rating on (BIAF) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

Spark’s Take on BIAF Stock

According to Spark, TipRanks’ AI Analyst, BIAF is a Neutral.

BIAF’s overall stock score of 51 reflects its financial instability due to high leverage and negative profit margins, despite some potential for revenue growth. Technical analysis indicates weak momentum, and the negative P/E ratio suggests valuation challenges. The lack of earnings call data and corporate events means these factors do not impact the score.

To see Spark’s full report on BIAF stock, click here.

More about bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. operates in the biotechnology industry, focusing on developing innovative diagnostic and therapeutic products.

Average Trading Volume: 11,992,788

Technical Sentiment Signal: Sell

Current Market Cap: $7.14M

Find detailed analytics on BIAF stock on TipRanks’ Stock Analysis page.